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Summary 
Pancreatic ductal adenocarcinoma (PDAC) represents the 90% of the forms of pancreatic 
cancers. The mortality rate is high due to its rapid dissemination, the strong resistance to the radio 
and chemotherapy, along with the lack of prognostic approaches. Unfortunately, a merely 20% 
out of the total diagnosed patients may go under treatment and the 5-year survival rate is less than 
5%. Therefore, this highlights the urgent need to find novel therapies along with new pancreatic 
cancer markers towards the early detection of the primary stages of the PDAC. 
PDAC solid tumours are constituted by heterogeneous populations. Cancer stem cells 
(CSC) are a unique subpopulation of cells within the tumour that possess stem properties such as 
self-renew, but also are able to give rise a diverse progeny with self-limited proliferative capacity 
which perpetuates the malignant growth and even promotes the invasion towards new tissues. 
These particular characteristics place them at the apex of an organized hierarchical system where 
CSC are responsible for the new generation of more differentiated progenies (non-CSC) and are 
accompanied by desmoplastic reactive stroma and immune cells. 
The identification and consequent isolation of pancreatic CSCs facilitated the generation 
of genetically engineered murine models. Nonetheless, the current models may not be 
representative for the spontaneous tumour occurrence.  
The present study show the generation of a novel pancreatic iPSC-converted cancer stem 
cell lines (CSCcm) as a cutting-edge model for the study of PDAC. Thus, CSCcm lines were 
exclusively achieved by means of the conversion of iPSCs using the influence of pancreatic 
cancer cell line PK-8 and KLM-1 conditioned medium (CM) and were not subjected to any 
genetic manipulation.  
The xenografts tumours resulting from both the subcutaneous and the orthotopic 
transplantation of CSCcm PK8 and CSCcm KLM-1 cell lines displayed histopathological 
adenocarcinoma-like morphologies and showed pancreatic cancer specific hallmarks as PanIN 
lesions and PDAC features. In addition, when CSCcm cell lines were orthotopically implanted 
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not only recapitulated the histological features of pancreatic cancer in the primary tumours but 
also displayed a preferential metastasis towards the liver as the current disease. Consistently, 
immunohistochemistry analysis for the lineage tracing marker GFP demonstrated that either the 
pancreatic lesions or the metastatic nodes were originated from CSCcm cell lines.   
A preliminary screening for the expression of the transcript levels for the most 
representative CSC markers revealed a strong enhancement for the primary culture CSCcm cell 
lines with a slight decrease in the subsequent generations, suggesting a possible establishment of 
a more differentiated phenotype. This was further confirmed by the molecular characterization 
from RNA-sequencing analysis which indeed highlighted primary culture cell lines (1st CSCcm) 
as potential candidates to represent the pancreatic CSCs and indicated the establishment of a more 
differentiated pancreatic cancer molecular pattern in their subsequent progenies 2nd CSCcm and 
3rd CSCcm.  
It is noteworthy that RNA-seq analysis revealed that the distinct CSCcm lines did not 
harbour single point mutations for the oncogene Kras codon 12 or 13 and that DESeq analysis 
showed increased expression of Myc in the 2nd CSCcm generation whilst it was remarkably 
downregulated in 1st CSCcm. The latter correlated with the recent findings on genome-wide DNA 
methylation profiling which determined CpG sites annotated to Myc to be highly methylated in 
pancreatic CSCs rather than in more differentiated pancreatic cancer cells. Furthermore, the 
overexpression of the Dnmt3a and Dntm3b observed in 1st CSCcm and the subsequent 
downregulation in 2nd CSCcm strongly suggested that the activation of Kras and Myc are required 
but not sufficient to originate a PDAC tumour and their turnover between 1st CSCcm and more 
differentiated 2nd CSCcm may be tightly related to epigenetic alterations.  
Even though the conditioned medium from cancer cell lines provides an appropriate 
microenvironment able to initiate a malignant transformation it is not until CSCcm get in touch 
with an in vivo system that the CSCs features become robust at the level of transcriptome. 
Therefore, the intervention of the organisms is still essential. Certainly, this reliance on in vivo 
systems is an unresolved matter that must eventually be overcome.  
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Overall, we conclude that PDAC-CSCcm model may provide new insights about the 
actual occurrence of the pancreatic cancer leading to develop different approaches to target CSCs 
and abrogate the progression of this fatidic disease.  
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Chapter 1 
 
 
 
Introduction to Pancreatic Cancer 
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Pancreatic cancer  
Epidemiology  
Pancreatic ductal adenocarcinoma (PDAC) the predominant form of pancreatic cancer is the 
6th leading cause of cancer-related death (6% of all cancer deaths) in Europe, with 104,481 
estimated deaths in 2012. The 5-year survival rate for PDAC is less than 5% (Figure 1).  
 
 
 
 
 
 
 
Figure 1. Estimated mortality for both sexes in Europe 2012. (EUCAN database http://eco.iarc.fr/eucan/Default.aspx  
2012 Eupancreas). 
According to mortality predictions for the year 2015 in the European Union, mortality of 
pancreatic cancer will keep increasing between 2009 and 2015 in both sexes (rising by 4% in men 
and 5% in women), becoming the fourth leading cause of cancer death with 8% and 6% of all 
cancer deaths in men and women, respectively (1). Projections of cancer incidence and mortality 
to 2030 also reveal that pancreatic cancer will become the second leading cause of cancer-related 
death in the US (2). 
 
Risk factors for PDAC 
The potential risk factors for developing pancreatic cancer are the age, gender, race, smoking, 
diabetes, familial history, inflammation of the pancreas, obesity and other risk factors mainly 
related to diet and genetic syndromes that are under active study (3, 4).  
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 Age: The risk of developing pancreatic cancer goes up as people age. Almost all patients 
are older than 45. About two-thirds are at least 65 years old. The average age at the time 
of diagnosis is 71. 
 Gender: Men are slightly more likely to develop pancreatic cancer than women. This may 
be due, at least in part, to higher tobacco use in men, which raises pancreatic cancer risk 
(see above). The difference in pancreatic cancer risk was larger in the past (when tobacco 
use was much more common among men than women), but the gap has closed in recent 
years. 
 Race: African Americans are slightly more likely to develop pancreatic cancer than 
whites. The reasons for this aren’t clear, but it may be due in part to having higher rates 
of some other risk factors for pancreatic cancer, such as diabetes, smoking in men, and 
being overweight in women. 
 Smoking: Pancreatic cancer risk is 2.2 times higher in current smokers compared with 
never-smokers, a pooled analysis showed. Risk increases with the number of cigarettes 
smoked per day, and duration of cigarette smoking, meta- and pooled analyses have 
shown.  
 Diabetes: Pancreatic cancer is more common in people with diabetes. The reason for this 
is not known. Most of the risk is found in people with type 2 diabetes. This type of 
diabetes most often starts in adulthood and is often related to being overweight or obese. 
It’s not clear if people with type 1 (juvenile) diabetes have a higher risk. 
 Family history: Pancreatic cancer seems to run in some families. In some of these families, 
the high risk is due to an inherited syndrome (explained below). In other families, the 
gene causing the increased risk is not known. Although family history is a risk factor, 
most people who get pancreatic cancer do not have a family history of it. 
 Inflammation of the pancreas: Chronic pancreatitis, a long-term inflammation of the 
pancreas, is linked with an increased risk of pancreatic cancer (especially in smokers), 
but most people with pancreatitis never develop pancreatic cancer. Chronic pancreatitis 
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is sometimes due to an inherited gene mutation. People with this inherited (familial) form 
of pancreatitis have a high lifetime risk of pancreatic cancer. 
 Obesity: Body fatness is classified by the International Agency for Research on Cancer 
(IARC) and the World Cancer Research Fund/American Institute for Cancer Research 
(WCRF/AICR) as a cause of pancreatic cancer. Abdominal fatness is classified by 
WCRF/AICR as a probable cause of pancreatic cancer. Pancreatic cancer risk increases 
by 10% per 5-unit body mass index (BMI) increase, a meta-analysis showed. Pancreatic 
cancer risk increases by 11% per 10cm waist circumference increase, and by 19% per 
0.1-unit waist-to-hip ratio increment, this meta-analysis showed. 
 Genetic syndromes: Inherited gene changes (mutations) can be passed from parent to 
child. These gene changes may cause as many as 10% of pancreatic cancers. Sometimes 
these changes result in syndromes that include increased risks of other cancers (or other 
health problems). 
 
Histology of Pancreatic cancer 
The pancreas is an organ located behind the stomach in the upper left abdomen. It is 
surrounded by other organs including the small intestine, liver, and spleen. It is spongy, about six 
to ten inches long, and is shaped like a flat pear or a fish extended horizontally across the abdomen. 
The wide part, called the head of the pancreas, is positioned toward the center of the abdomen at 
the juncture where the stomach meets the first part of the small intestine (Figure 2). 
It has two main functions: the exocrine which involves the acinar cells secreting enzymes that 
are transported into the small intestine by the pancreatic duct and are important to digestion and 
the endocrine that consists of islet cells (islets of Langerhans) that create and secrete important 
hormones such as glucagon, insulin, somatostatin, and pancreatic polypeptide (PP) directly into 
the bloodstream. 
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Figure 2. The pancreatic exocrine function involves the acinar cells secreting digestive enzymes that are transported 
into the small intestine by the pancreatic duct. Its endocrine function involves the secretion of insulin (produced by beta 
cells) and glucagon (produced by alpha cells) within the pancreatic islets. These two hormones regulate the rate of 
glucose metabolism in the body. The micrograph reveals pancreatic islets. LM × 760. (Micrograph provided by the 
Regents of University of Michigan Medical School © 2012). (The Endocrine System. Anatomy and Physiology. 
OpenStax). 
The majority of exocrine tumours found in the distal part of the pancreatic gland are 
adenocarcinomas. Commonly are differentiated as pancreaticobiliary adenocarcinomas 
resembling pancreaticobiliary duct epithelium, although less frequently found, they also may 
differentiate as intestinal type displaying intestinal/colon-like phenotype. Adenocarcinoma in the 
pancreas has a tendency to produce fibrous connective tissue making them very hard tumours. 
It has long been considered that pancreatic ductal adenocarcinoma arise from pancreatic ducts 
on the basis of its morphology, the occurrence of dysplasia in putative preneoplastic ductal lesions, 
and the absence of acinar dysplasia in the pancreas of patients with PDAC. However, evidence 
gathered through both in vitro studies and more importantly genetic mouse models of PDAC 
shows that ductal-type tumours can arise from acinar cells. These findings raise new important 
questions related to PDAC pathophysiology and call for in-depth studies of acinar cell 
differentiation in order to better understand PDAC biology (5). 
Three histologically defined preneoplastic precursor lesions to invasive adenocarcinoma of 
the pancreas have been identified. These include microscopic, non-cystic pancreatic 
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intraepithelial neoplasia (PanIN) and macroscopic, cystic intraductal papillary mucinous 
neoplasms (IPMN) and mucinous cystic neoplasms (MCN) (6, 7). 
Based on the international nomenclature and classification established by the assembly of 
Pancreatic Cancer Think Tank held in Park City, Utah in September 1999, we can currently define 
the preneoplastic lesions as following (7-10):  
 PanIN-1A: (Pancreatic Intraepithelial Neoplasia 1-A): These are flat epithelial lesions 
composed of tall columnar cells with basally located nuclei and abundant supranuclear 
mucin. The nuclei are small and round to oval in shape. When oval the nuclei are oriented 
perpendicular to the basement membrane. It is recognized that there is considerable 
histologic overlap between non-neoplastic flat hyperplastic lesions and flat neoplastic 
lesions without atypia. Therefore, some may choose to designate these lesions with the 
modifier lesion ("PanIN/[L]-1A") to reflect the fact that the neoplastic nature of many 
cases of PanIn-1A has not been established. 
 PanIN-1B: (Pancreatic Intraepithelial Neoplasia 1-B): These epithelial lesions have a 
papillary, micropapillary or basally pseudostratified architecture, but are otherwise 
identical to PanIN-1A. 
 PanIN-2: (Pancreatic Intraepithelial Neoplasia 2): Architecturally these mucinous 
epithelial lesions may be flat or papillary. Cytologically, by definition, these lesions must 
have some nuclear abnormalities. These abnormalities may include some loss of polarity, 
nuclear crowding, enlarged nuclei, pseudo-stratification and hyperchromatism. These 
nuclear abnormalities fall short of those seen in PanIN-3. Mitoses are rare, but when 
present are non-luminal (not apical) and not atypical. True cribriforming luminal necrosis 
and marked cytologic abnormalities are generally not seen, and when present should 
suggest the diagnosis of PanIN-3. 
 PanIN-3: (Pancreatic Intraepithelial Neoplasia 3): Architecturally, these lesions are 
usually papillary or micropapillary, however, they may rarely be flat. True cribriforming, 
budding off of small clusters of epithelial cells into the lumen and luminal necroses 
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should all suggest the diagnosis of PanIN-3. Cytologically, these lesions are characterized 
by a loss of nuclear polarity, dystrophic goblet cells (goblet cells with nuclei oriented 
towards the lumen and mucinous cytoplasm oriented toward the basement membrane), 
mitoses which may occasionally be abnormal, nuclear irregularities and prominent 
(macro) nucleoli. 
 Intraductal Papillary Mucinous Neoplasms (IPMNs): IPMNs are mucinous epithelial 
neoplasms which involve the main pancreatic duct or its major branches. They are larger 
than PanINs and therefore usually visible grossly or by radiologic imaging. IPMNs may 
extend into small ducts. In these cases serial (step) sections may be helpful in defining 
the relationship of the two lesions. 
 Mucinous cystic neoplasms (MCN): Mucinous cystic neoplasms are characterized by the 
presence of ovarian stroma and the absence of a connection to the duct system. These 
features and the larger size of mucinous cystic neoplasms help distinguish mucinous 
cystic neoplasms from PanINs. 
 
Key regulators in PDAC carcinogenesis  
The accumulation of somatic mutations, epigenetic modifications and changes in the 
micro-environment leads to the development of pancreatic cancer.  
Somatic mutations together with genomic rearrangements have been identified to drive 
tumorigenesis in pancreatic cancer (11, 12). The mutation in KRAS codon 12 is the most 
frequently found with a prevalence of ~30% in PanIN neoplasms and nearly 100% of advanced 
PDAC cases (13-15). In addition, somatic mutations in CDKN2A, TP53 and DPC4/SMAD4 are 
also observed in patients, although none as frequent as KRAS. 
The proto-oncogene KRAS encodes a small guanine nucleotide transferase (GTPase) 
which cycles between GTP-bound active and GDP-bound inactive states. Thus, while its 
activation is driven first by the dissociation of GDP followed by the later binding of the GTP 
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mediated by the guanine nucleotide exchange factors (GEFs), its inactivation is induced by the 
hydrolysis of GTP therefore returning to the GDP-bound promoted by GTPase-activating proteins 
(GAPs). Activating mutations of KRAS found in PDAC (point mutations at codon G12, G13 and 
Q61) impair its intrinsic GTPase activity by blocking the interaction with GAPs leading to its 
constitutive activation and therefore a persistent stimulation of downstream signalling pathways 
that drive many of the hallmarks of cancer, sustained proliferation, metabolic reprogramming, 
anti-apoptosis, remodelling of the tumour microenvironment, evasion of the immune response, 
cell migration and metastasis (15). 
The cell signalling pathways linked to KRAS are considerably complex and dynamic, 
since involve distinct downstream effectors such as the canonical Raf/Mek/Erk, 
phosphatidylinositol 3-kinase (PI3K)/3-phosphoinositide-dependent protein kinase-1 (Pdk1)/Akt, 
RalGDS/p38MAPK, Rac and Rho, Rassf1, NF1, p120GAP and PLC-ε (16, 17). However in the 
context of PDAC it is believed that oncogenic KRAS signalling passes through three main 
pathways: Raf/Mek/Erk, PI3K/Pdk1/Akt and the Ral guanine nucleotide exchange factor pathway. 
The inhibitory crosstalk between the PI3K/AKT and MAPK pathways at the level of AKT 
and RAF modulates proliferation of the cancer cells (18). This interaction depends on several 
parameters such as the cell type, the RTK input and even the time course of RTK activation what 
indeed does not make simple the elucidation of the involved mechanisms (19). Nonetheless 
Zmajkovicova et al (2013) found a novel crosstalk between PI3K/AKT and MAPK independent 
of the RTK receptors, which negatively regulates the PI3K signalling by means of the 
phosphorylation of Mek1 at T292 by Erk resulting in the activation of the complex 
MAGI1/Mek1/PTEN. Therefore, the inhibition of the MAPK pathway likely interferes PTEN 
tumour suppressor function leading to PI3K pathway activation. The loss of PTEN and the 
subsequent activation of the PI3K pathway has been found in PDAC and shown to accelerate 
tumour formation. This has been attributed to increase the NFκB survival signalling and pro-
tumourigenic changes in the tumour microenvironment (20).  
16 
 
The oncogenic KRAS signalling is the main driving force behind PDAC. The signalling 
networks are characterised by the activation of several effector pathways and these are 
interconnected at various levels by cross-signalling and feedback loops (Figure 3). 
 
  
 
 
 
 
 
 
 
Figure 3. An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling networks in 
pancreatic cancer. (Eser, S. et al. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer 2014 
111, 817–822). 
As it has been aforementioned approximately 5–10% of patients have a family history of 
the disease (15). Penetrant germline mutations have been found in the tumour suppressors 
CDKN2A, BRCA2, PALB2, ATM and STK11, the DNA mismatch repair gene MLH1, as well 
as in the hereditary pancreatitis associated genes PRSS1and SPINK1, and the cystic fibrosis gene 
CFTR (21-23). Recent genome wide association studies (GWAS) identified multiple loci that 
harbor common germline susceptibility variants with small effect sizes located in intergenic or 
intronic regions on chromosomes 1q32.1 (NR5A2) 5p15.33 (TERT/CLPTM1L), 9q34.2 (ABO), 
13q22.1 (nongenic) in populations of European descent, and on 3q29 (TFRC), 5p13.1 (DAB2), 
6p25.3 (FOXQ1), 7q36.2 (DPP6), 10q26.11 (PRLHR), 12p11.21 (BICD1), 21q21.3 (BACH1), 
21q22.3 (TFF1) and 22q13.32 (FAM19A5), in Asian populations (15). Furthermore, mutations 
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in HNF1A, HNF1B, HNF4A and PDX1 can each cause maturity onset diabetes of the young, and 
SNPs localizing within the NR5A2, HNF1A, PDX1 and HNF1B gene regions have been 
identified as markers of pancreatic cancer risk loci through GWAS or pathway based GWAS 
analyses. Interestingly, unlike it has been reported so far recent transcriptome analysis in PDAC 
described HNF1A and HNF1B, PDX1 and PTF1A to be among the top five most consistently 
dysregulated sub-networks (15). Nonetheless, new integrated genomic analysis identified 32 
recurrently mutated genes that were aggregated into 10 pathways: KRAS, TGF-β, WNT, NOTCH, 
ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and 
RNA processing. The subsequent expression analysis defined 4 new subtypes of PDAC: (1) the 
squamous which are enriched for TP53 and KDM6A mutations, the upregulation of the TP63ΔN 
transcriptional network together with the hypermethylation of pancreatic endodermal cell-fate 
determining genes and have a poor prognosis; (2) the pancreatic progenitor that preferentially 
express FOXA2/3, PDX1 and MNX1 which are involved in early pancreatic development; (3) the 
immunogenic subtype containing upregulated immune networks including pathways involved in 
acquired immune suppression; and (4) the aberrantly differentiated endocrine exocrine (ADEX) 
which displayed the upregulation of genes that regulate networks involved in KRAS activation, 
exocrine (NR5A2 and RBPJL), and endocrine differentiation (NEUROD1 and NKX2-2 (26, 27).  
Studies of Genome-wide analysis of promoter methylation associated with gene 
expression attributed aberrant gene hyper- and hypo- methylation to contribute to the 
development and progression of pancreatic cancer (28, 29). Consistently, aberrant methylation 
increases during neoplastic development among the PanINs and IPMNs (29, 30). Among the list 
of 1206 candidate BAI1, KCNV1, EYA4, BNC1, HOXA5, PAX7, SOX14, TLX3, NRXN1, 
CNTNAP2, PKP1, ACTA1, MDFI, EVC2, LIN28, NRN1, PENK, m FAM84A, and ZNF415 
were found to be hypermethylated. Whereas within the differential methylation profiles of genes 
whose epigenetic was silenced included NPTX2, CLDN5, LHX1, WNT7A, FOXE1, PAX6, 
BNIP3, GADD45B, HIC1, HS3ST2, TWIST1, IRF7, CCNA1, ALPP, CEBPA, CACNA1G, 
CCND2, and TFPI-2. Interestingly, DNA hypermethylation of genes involved in stem cell 
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pluripotency, such as the intestinal stem cell marker and chromatin structure regulator BMI1, the 
genes encoding bone morphogenetic proteins BMP3, BMP6, the transcription factors FOXD3, 
CDX2, UTF1, and T, as well as NR5A1, NR5A2, NR2F1, NTRK1, NTRK2, NTRK3, NODAL, 
SALL4, and SPHK1 genes were also identified (31). 
Overall, the identification of the accumulated somatic mutations, the aberrantly 
hypermethylated and silenced genes with the elucidation of the epigenetic mechanisms are crucial 
for the improvement of diagnosis, prognostic and therapeutic applications. 
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Chapter 2 
 
 
 
Cancer Stem Cells and Tumour Microenvironment  
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Cancer Stem Cells 
The distinctive characteristic of cancer is the heterogeneity. The major evidence is the 
diversity present in the subpopulations of the neoplastic cells within the same tumours which 
strongly describes the co-existence of cancer cells in a multiple levels of differentiation. The 
diversification give rise to different functional properties throughout the cancer progression. This 
might be due to the genome instability along with the epigenetic modifications. The heterogeneity 
may be defined as the intratumoral heterogeneity and intertumoral heterogeneity referring to the 
molecular differences conferred by tumours initiated in the same organ which allows the 
classification of these tumours and even representing biologically distinct disease entities.  Thus, 
in the context of the intratumoral heterogeneity the categories that are comprehended are at the 
level of functionality, phenotype and indeed genetically. Consequently, distinct members co-exist 
and interact within the same cohort of cells and these interactions may represent one of the major 
causes responsible of modulating their nature (1, 2).  
A unique subpopulation of cells that possess stem properties such as self-renew but also, 
are able to give rise a diverse progeny with self-limited proliferative capacity thereby perpetuating 
the malignant growth and even promoting the invasion towards new tissues, receive the name of 
cancer stem cells (CSC) and their characteristics place them at the apex of an organized 
hierarchical system within the tumour in where CSC are responsible for the new generation of 
more differentiated progenies (non-CSC) (1-3).  
The origin of the CSC is a question that remains to be elucidated and several studies are 
emerging in order to address this point. Different origins have been hypothesized however the 
controversy is mainly serve in a dichotomy manner between the clonal evolution and the CSC 
paradigm model. The popular theory of Peter Nowell described almost four decades ago about 
the clonal evolution wherein a single cell undergoes to a sequential cloning leading up to the 
tumour progression by means of the selection of the most aggressive subclones due to the stepwise 
acquisition of mutations, has been preserved until nowadays (Figure 1). 
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Figure 1. Clonal Evolution and Clonal Relationships. As shown in Panel A, selection operates on the phenotypes 
termed the “hallmarks” of cancer, giving rise to clones of cells with different properties. Not all properties lead to 
expansions — for example, increased senescence may lead to eventual stasis or loss of a clone. The acquisition of 
somatic mutations and alterations in the epigenome (indicated by arrows) can be phenotypically neutral or lead to the 
acquisition of new phenotypes (cells shaded with distinct colors). As shown in Panel B, progressive accumulation of 
mutations or other heritable properties leads to clonal relationships. Letters denote a mutation or heritable mark. Colors 
represent distinct groupings of cells related by descent (clones). Many relationships are possible — for example, 
mutation G co-occurs independently, leading to two distinct clonal genotypes containing G. The presence of mutations 
does not necessarily imply selection; the tree depicted could arise owing to random genetic drift. Normal or supporting 
cells are omitted from this schematic (Samuel Aparicio, B.M. et al. The Implications of Clonal Genome Evolution for 
Cancer Medicine. N Engl J Med 2013; 368:842-851). 
 
In contrast, the CSC paradigm theorize that within a tumour cells only an small and 
exclusive subpopulation possess self-renewal ability and have the potential to give rise to a variety 
of transit amplifying cells that divide a certain number of times then differentiate into specialized 
tumour cells and that unlike their progenitors display limited proliferation and tumorigenicity. 
Thereby CSC paradigm suggests that tumours may grow like normal tissues of the body. 
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Figure 2. Cancer theories: The cancer stem cell theory suggests a clear hierarchy of cells within a tumour. The 
stochastic model says that tumour growth is a random process to which all cells can contribute. (Blanpain, C. et al. 
EuroStemCell. 2015). 
 
According to this, the cells within the tumour are in a strictly organised system wherein 
CSC are at the top of the hierarchy giving rise to more differentiated cancer cells. 
On the other hand, inside the CSC paradigm has been proposed a stochastic model of 
cancer growth. This model explains the tumour growth from different and new approach. This 
theory argues that all cancer cells have the same potential to grow and divide but each cell is 
attributed randomly between self-renewal and differentiation. The cells in a tumour are not in an 
organised system – any cell has the same intrinsic potential to contribute to tumour growth. In 
fact, different types of cancer may work in different ways, so it is possible that both of these 
theories are right. Perhaps they apply to different cancers or different stages of tumour 
development (Figure 2). 
The clonal evolution and the two CSC paradigm models are not mutually exclusive, the 
difficulties in finding clear evidences to discern the main origin are notorious and recent reports 
suggest that even might exist differences in the origin depending on the type of disease (4-6).  
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However, our recent data provided new insights that will change the current picture of the CSC 
paradigm and the clonal evolution theories. 
 
 Tumour Cell Plasticity 
The tumour cell plasticity comprised the possibility that a non-CSC undergoes to 
differentiation which ends up turning into a cancer cell endowed of stem-like properties. This 
bidirectional transformation from non-CSC to CSC has been found in different tumours such as 
glioma, intestinal tumours and certain types of breast cancers, wherein the common mechanisms 
are the dysregulation of specific genetic pathways which dictates the emergence and phenotype 
of the disease.  
The process of dedifferentiation refers to the loss of mature functional features and the 
subsequent possible re-acquisition of the embryonic properties. This concept has been 
controversial but latest reports reinforcing its existence suggested that could be involved in the 
transition for tumorigenesis. Thus, the reversion of the differentiation to a stem cell phenotype 
may suppose an oncogenic transformation.  
Despite the apparent differences, every time more the importance of the balance of the 
tissue homeostasis is becoming more relevant and appears to be the common fact throughout all 
cancer types. Thus the consequences because of the changes in the tissue homeostasis, known as 
a tumour microenvironment, exert a major influence in the cell fate and may be decisive for the 
occurrence of the disease (1-6). 
 
Tumour Microenvironment (TME)  
It has been appreciated for some time that the tumour microenvironment (TME) plays a 
significant role in disease progression, but the precise function of each constituent remains 
unknown. The TME is constitute by stroma cells and the essential elements that are found to be 
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part of include fibroblasts, myofibroblasts, neuroendocrine cells, adipose cells, immune and 
inflammatory cells, the blood and lymphatic vascular networks, and the extracellular matrix 
(ECM). The stroma is critical for maintaining the physiological normal tissue homeostasis and 
recent studies strengthened the concept that some stromal components have anticancer activities 
by regulating immunosuppression and restraining carcinogenesis. Contrary to the stipulated 
regular conditions the variety of infiltrating immune cells, cancer-associated fibroblasts (CAF) 
and angiogenic endothelial cells play expanding and critical functions in sustaining cell 
proliferation, evading growth suppressors, promoting survival, activating invasion and metastasis, 
and reprogramming energy metabolism (7, 8).  
 It has been reported the ability of the cancer cells to regulate or modify the stromal cells 
favouring the cancerous niche by means of the synthesis of cytokines, chemokines and growth 
factors which consequently accelerate the progression of disease. This stromal cell plasticity leads 
to respond rapidly to neoplastic situations and act in concert with the adjacent epithelium in 
eliciting the emergence of “reactive stroma” (9).  
In a solid tumour those cancer cells that are in the invasive front are exposed to the 
reactive stroma, hypoxia and immune surveillance. Thus the invasive front is rich in CAFs, 
tumour-associated macrophages (TAMs), myeloid progenitor cells and newly generated blood 
vessels (10). The invasive fronts rich in CAFs and myofibroblasts produces TME-mediated 
signalling expressing high levels of extracellular factors including chemokine CXC motif ligand 
12 (CXCL12), chemokine CC motif ligand 2 (CCL2), CCL8, and insulin-like growth factor 
binding protein 7 (IGFBF7) promoting the inflammatory response and recruiting immune cells, 
and also cytokines such as TNF-α, TGF-β, hedgehog (Hgh), Wnt and Notch that are attributed to 
the survival and fitness of CSCs (8-11).  
TGF-β stimulates the epithelial-mesenchymal transition (EMT) thus the carcinoma cells 
in the invasive front of tumour lose the cell-to-cell adhesion and apical-basal polarity and gain 
migratory behaviour. Particularly, in pancreatic cancers the enforced expression of EMT 
transcription factors confers the gain of stem-like features (12). On the other hand TNF-α which 
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is a crucial growth factor is expanded and released by TAMs establishing paracrine loops 
supporting back the cancer cells (9). In addition, TNF-α has been also found to stimulate the 
accumulation of reactive oxygen species (ROS) as well as promote the nuclear entry of β-catenin 
activating Wnt/β-catenin pathway in surrounding epithelial cells which regulates the stem cell 
pluripotency and cell fate decisions (Figure 3) (7, 8). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The conserved Wnt/β-Catenin pathway regulates stem cell pluripotency and cell fate decisions during 
development. This developmental cascade integrates signals from other pathways, including retinoic acid, FGF, TGF-
β, and BMP, within different cell types and tissues. The Wnt ligand is a secreted glycoprotein that binds to Frizzled 
receptors, leading to the formation of a larger cell surface complex with LRP5/6. Frizzleds are ubiquitinated by ZNRF3 
and RNF43, whose activity is inhibited by R-spondin binding to LGR5/6. In this manner R-spondins increase sensitivity 
of cells to the Wnt ligand. Activation of the Wnt receptor complex triggers displacement of the multifunctional kinase 
GSK-3β from a regulatory APC/Axin/GSK-3β-complex. In the absence of Wnt-signal (Off-state), β-catenin, an integral 
E-cadherin cell-cell adhesion adaptor protein and transcriptional co-regulator, is targeted by coordinated 
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phosphorylation by CK1 and the APC/Axin/GSK-3β-complex leading to its ubiquitination and proteasomal 
degradation through the β-TrCP/Skp pathway. In the presence of Wnt ligand (On-state), the co-receptor LRP5/6 is 
brought in complex with Wnt-bound Frizzled. This leads to activation of Dishevelled (Dvl) by sequential 
phosphorylation, poly-ubiquitination, and polymerization, which displaces GSK-3β from APC/Axin through an unclear 
mechanism that may involve substrate trapping and/ or endosome sequestration. Stablized β-catenin is translocated to 
the nucleus via Rac1 and other factors, where it binds to LEF/TCF transcription factors, displacing co-repressors and 
recruiting additional co-activators to Wnt target genes. Additionally, β-catenin cooperates with several other 
transcription factors to regulate specific targets. Importantly, researchers have found β-catenin point mutations in 
human tumors that prevent GSK-3β phosphorylation and thus lead to its aberrant accumulation. E-cadherin, APC, R-
spondin and Axin mutations have also been documented in tumor samples, underscoring the deregulation of this 
pathway in cancer. Wnt signaling has also been shown to promote nuclear accumulation of other transcriptional 
regulator implicated in cancer, such as TAZ and Snail1. Furthermore, GSK-3β is involved in glycogen metabolism and 
other signaling pathways, which has made its inhibition relevant to diabetes and neurodegenerative disorders. (Cell 
Signaling Technology. Created January 2003-revised September 2016. www.cellsignal.com). 
 
Inflammation and Tumorigenesis 
Inflammation has an important role in the tumour initiation. Activated inflammatory cells 
serve as source of ROS, RNI, growth factors and indeed cytokines that as it has been 
aforementioned may confer stem-like properties upon the tumour progenitors or even induce the 
expansion of stem cells (13). 
The contribution of myeloid cells to the tumour play a crucial role in promoting tumour 
progression, angiogenesis, cell invasion and metastasis. Specifically, mast cells are commonly 
seen in various tumours and have been implicated in the regulation of tumour initiation and 
development. They are likely the most productive chemical factory in the body and influence 
other cells through both soluble mediators and cell-to-cell interaction, thereby have the capacity 
to promote tumour proliferation and invasion both directly by stimulating tumour cells and 
indirectly by modulating the TME (14). High number of mast cells may be found at the invasive 
border of tumours. Since they are potent inducers of fibrosis and stimulate fibroblast and 
myofibroblast proliferation   it may lead to the tissue reorganization and the consequent reactive 
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tumour stroma. In addition, their high source of proteases confer them the ability to degrade the 
extracellular matrix therefore facilitating the tumour growth and dissemination (15, 16). It has 
also been seen that the outcome of cancer may come determined by the intricate interaction from 
mast cells with the regulatory T cells (Treg). TNFα produced by mast cells upregulates OX40 in 
Treg and activates the PI3K pathway, while MC IL6 works through pg130 to stimulate the JAK–
STAT3 pathway, allowing expression of IL17. Proinflammatory properties of Treg may help to 
propagate tumor growth and dissemination and since mast cells expand in polyps and tumours of 
the gastrointestinal tract, it is tempting to suggest that mast cells turn the tide in favour of cancer 
progression by recruiting and then altering the functions of Treg to promote further cancer-
associated inflammation. (14).  Thus, mast cells appear to have an indispensable role in the 
development of solid tumours by promoting a gradual gain of pro-inflammatory properties with 
the participation of Treg cells therefore favouring uncontrolled escalation of cancer inflammation, 
tumour immune tolerance, and aggressive tumour growth.  
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Chapter 3 
 
 
 
A new PDAC mouse model originated from 
 iPSCs-converted pancreatic Cancer Stem Cells (CSCcm) 
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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is the most representative form of pancreatic 
cancers. PDAC solid tumours are constituted of heterogeneous populations of cells including 
cancer stem cells (CSCs), differentiated cancer cells, desmoplastic stroma and immune cells. The 
identification and consequent isolation of pancreatic CSCs facilitated the generation of 
genetically engineered murine models. Nonetheless, the current models may not be representative 
for the spontaneous tumour occurrence. In the present study, we show the generation of a novel 
pancreatic iPSC-converted cancer stem cell lines (CSCcm) as a cutting-edge model for the study 
of PDAC. The CSCcm lines were achieved only by the influence of pancreatic cancer cell lines 
conditioned medium and were not subjected to any genetic manipulation. The xenografts tumours 
from CSCcm lines displayed histopathological features of ADM, PanIN and PDAC lesions. 
Further molecular characterization from RNA-sequencing analysis highlighted primary culture 
cell lines (1st CSCcm) as potential candidates to represent the pancreatic CSCs and indicated the 
establishment of the pancreatic cancer molecular pattern in their subsequent progenies 2nd CSCcm 
and 3rd CSCcm. In addition, preliminary RNA-seq SNPs analysis showed that the distinct CSCcm 
lines did not harbour single point mutations for the oncogene Kras codon 12 or 13. Therefore, 
PDAC-CSCcm model may provide new insights about the actual occurrence of the pancreatic 
cancer leading to develop different approaches to target CSCs and abrogate the progression of 
this fatidic disease.  
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Introduction 
PDAC is one of the most highly desmoplastic tumours which unfortunately due to its 
aggressiveness and rapid dissemination together with the strong resistance to the radiation therapy 
and chemotherapy contributes to the dismal prognosis. Over the past decades the strategies to find 
new diagnostic approaches at early stages along with the effective treatments has not improved 
significantly (1, 2). Therefore, this highlights the urgent need to find novel models to study the 
origin as well as the progression of the disease. 
PDAC solid tumours are comprised of a wide range of heterogeneous populations of cells 
including cancer stem cells (CSCs), the actual differentiated cancer cells together with 
desmoplastic stroma and immune cells which represent a high proportion of the tumour mass (3).  
CSCs are considered as cells that possess stem cell properties and produce diverse lineages of 
cancer cells. Hence, CSCs have been associated with the tumour initiation and progression, and 
have been reported to be involved in tumour metastasis (4). 
The isolation of pancreatic CSCs succeeded in providing new insights regarding the 
chemoresistance and the high metastatic ability in PDAC. Since CSCs and non-CSCs share an 
identical genetic background it is difficult to find appropriate in vitro and in vivo systems that 
allows to select reproducibly and exclusively enriched CSCs populations. Furthermore, these new 
approaches include particular markers that are also found in differentiated adult cells what makes 
questionable the identification of the CSCs (7). Recent advances have been developed in targeting 
CSCs and their identification and isolation consequently facilitate the generation of new murine 
models (5, 6). However, the current models are genetically engineered and therefore may not be 
suitable for a better understanding of the spontaneous tumour occurrence.  
As have been seen in regenerative medicine field, iPSCs when exposed to appropriate 
environments are able to directly differentiate into progenitor cells that lead to the latter matured 
form of cells. Hence, the signals found in the niche simultaneously regulate the differentiation as 
well as support the tissue homeostasis preserving the self-renewal potential from a minor but 
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required stem cells number (8). Based on this we previously hypothesized that CSCs might be 
considered as progenitor cells that are destined to differentiate into cancer cells and that 
consequently if the cell fate comes determined by the events and factors present in the niche, the 
tumour microenvironment should exert the same effects when healthy cells are exposed to it. 
Chen L and Kasai T et al. demonstrated the impact of the so-called cancerous niche when by 
exposing Nanog iPSCs to a Lewis Lung carcinoma conditioned medium (LLCcm) a malignant 
tumour was obtained exhibiting angiogenesis in vivo, capacity of self-renewal and expressed 
markers associated to stem cell properties and undifferentiated state such as Nanog, Rex1, Eras, 
Esg1 and Cripto. In contrast, when control Nanog iPSCs were implanted into Balb/c nude mice 
formed typical teratomas displaying contained differentiated tissues without metastasis. Thus a 
new model of CSC-like cells generated exclusively under the influence of the microenvironment 
was proposed (9). 
In the present study, we show the generation of a novel pancreatic iPSC-converted cancer 
stem cell lines (CSCcm) together with the subsequent characterization of the tumours obtained as 
a result from the transplantation of the CSCcm lines in vivo demonstrating that CSCcm is a 
promising cutting-edge model for the study of PDAC occurrence and progression.  
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Results  
iPSCs-converted CSCs (CSCcm) display CSCs features   
As described in the protocol established by Chen L and Kasai T et al., to generate a model 
of pancreatic CSCs, iPSCs were exposed to different conditioned medium (CM) from pancreatic 
carcinoma cell lines PK-8CM and KLM-1CM, a process named as conversion (Figure 1A) (9). 
Similarly to the established protocol, iPSCs were maintained in feeder-less conditions and the 
Leukemia inhibitory factor (LIF) which is essential for their viability was removed from the 
medium and thereby restricting them to the effect exclusively of the conditioned medium. 
Whereas the iPSCs cultured only with iPSCs media without LIF expired after 7 to 10 days (Figure 
1B), the viability and proliferation of the cells maintained in presence of conditioned medium was 
not affected. Nanog iPSCs cells were generated by the retrovirus-mediated introduction of the 
four factors Sox2, Oct3/4, Klf4 and c-Myc into the Nanog-GFP-IRES-Puror of mouse embryonic 
fibroblast (42), therefore iPSCs could be monitored throughout the conversion by the GFP 
expression as a validation of the stemness. The population of converted cells displayed a diverse 
pattern of differentiation harbour cells expressing strong to moderate GFP and other differentiated 
cells which the expression was null. Once the process was completed the cells were termed as 
CSCcm PK8 and CSCcm KLM-1 and their stem-like properties were tested through sphere 
suspension assay (Figure 1B).  
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Figure 1. A) Representative scheme of the conversion procedure. B) Viability of iPSCs maintained in control medium 
without LIF was no longer than 10 days. iPSCs underwent differentiated with no remaining GFP positive cells and 
eventually expired (upper panel). Stemness tracking during conversion by the presence of GFP protein. Self-renewing 
potential was validated by sphere formation assay previously to the subcutaneous implantation (lower panel). Original 
magnification 4x and 20x. 
Since the CSCcm population was heterogeneous, in order to ensure a high frequency of 
cells displaying CSC-like properties, 104, 105 and 106 cells from the two new pancreatic CSCcm 
lines were subcutaneously transplanted into immunocompromised Balb/c nude mice. After 30 
days, CSCcm engrafted and generated tumours in 9 out of 9 mice for each cell line indicating 
experimental reproducibility and demonstrating their tumorigenic potential. Chen and Kasai et al. 
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previously shown that iPSCs cultured under control medium generated benign teratoma. 
Consistently, the xenograft tumours histology showed specific characteristics that resembled the 
actual pancreatic ductal adenocarcinoma phenotype. Primary tumours were rich in stroma and 
among the epithelial-like structures pancreatic intraepithelial neoplastic lesions (PanIN) lesions 
were found together with moderate to poorly differentiated ductal structures (Figure 2A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A) Histopathological features of 1st CSCcm primary tumours were evaluated by H&E staining. Specific 
PanIN lesions are indicated with arrowheads. Original magnification 10x and 20x. B) Lineage tracing by GFP protein 
showed that it was predominantly expressed in undifferentiated cells, however was also partially found in ductal-like 
structures. Original Magnification 10x and 20x. 
Primary Tumour 1st CSCcm PK8 Primary Tumour 1st CSCcm KLM1 
A 
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 To further validate the PDAC-like structures arose from CSCcm we explored the 
expression of GFP protein in primary tumour. GFP expressing cells were found all over the tissue 
samples and although it was predominantly located by undifferentiated cells few epithelial cells 
from ductal-like structures remained positive for its expression (Figure 2B). When the expression 
of specific CSC markers CD133, CD24a and EpCAM was evaluated, their up-regulation was 
already observed in CSCcm and was similarly detected or even enhanced in primary cultures (1st 
CSCcm) (Figure 3A). CD133 is preferentially used in the identification of CSC in pancreatic solid 
tumours and its expression is commonly found within the ductal structures. Likewise the primary 
CSCcm tumour tissues showed a strong signal within the ductal-like structures (Figure 3B) 
confirming their malignant phenotype. 
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Figure 3. A) RT-qPCR analysis of CSCs markers CD133, CD24a and EpCAM in converted cells CSCcm and primary 
cultures 1st CSCcm. B) Upper micrographs showing the CD133-satined tissues from 1st CSCcm tumour. Positive 
expression was mainly located in ductal cells. Negative control for CD133 expression is shown in lower panel. Original 
magnification 15x and 10x.  
Primary cultures 1st CSCcm were enriched by puromycin allows the possibility to select 
the lineage from the top level of hierarchical system obtaining the corresponding lineage from the 
top of the cell hierarchy system and avoiding the intrusion of cells from the host. As compared to 
CSCcm it was noteworthy that 1stCSCcm generated a specific cell distribution composed by well-
defined colonies surrounded by myofibroblast-like cells most likely PSCs (pancreatic stellate 
cells). This particular feature of generating a spontaneous self-supporting system for the integrity 
and maintenance of the 1st CSCcm population was not observed neither in iPSCs control nor 
B 
42 
 
Primary Cultures 1st CSCcm 
1
st
 CSCcm 2
nd
 CSCcm 3
rd
 CSCcm 
PK8C
M 
KLM1C
M 
CSCcm 
CSCcm cultures, therefore might be considered as an indicative of their enhanced malignant 
transformation (Figure 4). 
 
 
 
 
Figure 4.  Cell distribution of primary cultures (1st CSCcm) after puromycin enrichment. 
 
Serial Transplantation leads to a more established PDAC phenotype 
With the purpose to assess whether CSCcm display long-term tumorigenic potential we 
performed serial transplantation. Thus, cells from 1st CSCcm were transplanted into secondary 
and subsequently into a tertiary nude mouse (Figure 5).  
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Figure 5. Serial transplantation scheme and images from sequential excised tumours obtained from subcutaneously 
transplanted CSCcm and 1st CSCcm primary cultures. Primary tumours and their corresponding metastatic liver nodes 
generated from orthotopically implanted 2rd CSCcm cells are also shown. Experiments were equally performed for both 
PK8CM and KLM1CM lines.  
 
Similarly to the primary culture the cells from secondary culture (2ndCSCcm) as well as 
tertiary cultures (3rdCSCcm) were enriched by puromycin. Thereby 1stCSCcm PK8 and 1stCSCcm 
KLM-1 were subcutaneously transplanted giving rise tumours within a short period of time of 
25days. Next, 2ndCSCcm PK8 and 2ndCSCcm KLM-1 were subsequently transplanted, however 
this time cells were orthotopically transplanted into the pancreas generating tumours within 15-
20days. Orthotopic tumours were remarkably bigger and specific liver metastasis was found 
(Table 1).   
Table 1. Primary CSCcm tumours from PK8CM cell lines and KLM-1CM cell lines obtained after the serial 
transplantation.   
Primary Tumours Time (days) Volume (mm3) Metastasis 
1st CSCcm PK8 30 2300 No 
2nd CSCcm PK8 25 2600 No 
3rd CSCcm PK8 20 3000 Liver 
1st CSCcm KLM1 30 2500 No 
2nd CSCcm KLM1 28 2100 No 
3rd CSCcm KLM1 18 3000 Liver 
 
Interestingly, subcutaneously transplanted tumours displayed indistinguishable 
histopathological morphologies whereas orthotopic primary tumours were richer in stroma mostly 
located in the inner mass and less epithelial ductal-like structures were found at the edges of the 
tumour. This may likely be due to difference in differentiation time whereby the myofibroblast-
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like phenotype is acquired earlier the epithelial-like phenotype requires a longer period of time 
(Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Micrographs from serial primary tumours showing the histopathological adenocarcinoma-like morphology 
by H&E staining. Original magnification 4x. 
 
When the liver metastatic nodes were examined a remarkable difference in the 
histopathological features was observed. Unlike primary tumours, liver metastatic nodes 
displayed a teratocarcinoma phenotype containing very few structures corresponding to PDAC. 
To determine that CSCcm had the ability to metastasise we searched evidences of GFP protein. 
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Its expression was strongly localised in areas with undifferentiated embryonic-like cells and no 
evidences were seen in more differentiated regions (Figure 7). 
 
 
 
 
 
 
 
 
 
Figure 7. Comparison of the histopathological features between 3rd CSCcm primary tumours and 3rd CSCcm liver 
nodes. 3rd CSCcm primary tumours displayed adenocarcinoma-like phenotype while a clear teratocarcinoma structure 
was found in liver nodes. GFP protein expression was shown to be located in undifferentiated cells areas within the 
liver metastatic nodes. Original magnification 10x. 
 
 This difference made us question the integrity of CSCcm and whether a possible 
reversion towards the iPSCs phenotype was occurring. Nonetheless, complementary lines of 
investigation by our group reported tumours harbouring adenocarcinoma phenotype when 
transplantations were held into mammary gland and confirmed the teratocarcinoma phenotype 
when transplanted directly into the liver most likely because of the strong endocrine potential that 
liver microenvironment owns (data not shown). Thus, determining the major influence that the 
microenvironment exerts on the CSCcm fate.   
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Given that the reprogramming of iPSCs was performed with the proto-oncogenes Sox2, 
Oct3/4, Klf4 and c-Myc, and that the implication specifically of c-Myc and Klf4 have been linked 
to PDAC we explored the expression of the transgenes in order to determine that there was no 
residual activity (Figure 8A). On the other hand the transcript levels of endogenous c-Myc, which 
is generally overexpressed in PDAC, were notably increased (Figure 8B). Hence, strongly 
supported that the malignant transformation arose by means of the intrinsically activated 
mechanisms of the cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. A) Agarose gel images from RT-qPCR products for the detection of Klf4 and cMyc transgenes. GAPDH was 
taken as a housekeeping control gene. B) Transcript levels for the mRNA of endogenous c-Myc were analysed by RT-
qPCR in a panel of serial transplantation samples.   
B 
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Even though the resulting CSCcm populations from the serial transplantation gave rise to 
more aggressive phenotype, with regard to the assessment of pancreatic CSC markers intriguingly 
a decreased expression was observed in 2ndCSCcm and 3rdCSCcm suggesting a possible 
establishment of the lineage that results into more differentiated pancreatic cancer cells (Figure 
9). This is later discussed by RNA-seq DEG analysis that demonstrated an up-regulation of the 
pancreatic cancer cell hallmarks (Figure 6C).  
 
 
 
 
 
 
 
 
Figure 9. RT-qPCR analysis of the preferentially expressed CSCs markers in a panel of serial transplantation samples. 
 
Characterization of CSCcm lines and primary tumours by PDAC hallmarks 
Bailey P. et al. (March 2016) presented a new definition for 4 pancreatic cancer subtypes 
based on an integrated genomic analysis. Among these 4 different subtypes is found the pancreatic 
progenitor class wherein the main transcriptional networks are comprised by transcription factors 
involved during the embryonic pancreatic differentiation (10). In order to assess PDAC 
characteristics in the serial CSCcm lines, we hypothesise that CSCcm populations most likely 
may share similar molecular pattern as found in the pancreatic progenitor subtypes. Within the 
main transcription factors described by Bailey P. et al, PDX1, FOXA2 and HES1 were cited to 
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be essentially expressed in the progenitor subtype. Thus, their transcript levels were examined 
along with the KRAS which is well-known to be involved in PDAC. Despite the variation found 
between the populations most likely due to the uncontrollable fate of the lineage, the up-regulation 
was apparent for all pancreatic progenitor markers as well as it was for KRAS (Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Pancreatic progenitor markers Pdx1, Foxa2 and Hes1 mRNA transcript levels and Kras mRNA expression 
levels were analysed through RT-qPCR analysis in a panel of all serial transplantation samples. 
 
Likewise to the described pancreatic progenitor class, the adenocarcinoma markers 
MUC1 and MUC5aC were co-expressed in all CSCcm tumours samples (Figure 11) specifically 
located at the membrane of epithelial ductal cells. Interestingly few structures that presented 
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ductal ectasia displayed strong expression in the infiltrating immune cells. Therefore these 
evidences infer in the achievement of CSCcm lines to recapitulate the PDAC phenotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. The adenocarcinoma phenotype was evaluated through the expression of the apomucinous of MUC1 and 
MUC5aC expression was predominantly located in the membrane of ductal structures. Infiltrating ductal immune cells 
also displayed high expression was also observed in mucinous ductal ectasia (MDE). Original magnification 4x. 
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Primary Tumor  
3rd CSCcm KLM1 
A possible model for lineage tracing ADM events  
The acinoductal metaplasia (ADM) describes the process whereby the islet neogenesis is 
accompanied by the transdifferentiation of the normal exocrine tissue into ductal complexes. This 
pancreatic metaplasia may turn into a premalignant state by means of progressive changes in the 
ductal epithelium that gives rise to PanIN lesions and may eventually lead to the progression of 
PDAC (11, 12).  Thus, proposed linear progression models for PDAC where ductal cells evolve 
into hyperplastic and later into dysplastic epithelium resulting in an invasive carcinoma had to be 
reconsidered since there are no formal evidences of these sequential events. Instead, in vitro and 
genetically engineered mouse models of PDAC have shown that tumours can arise from acinar 
cells (7). 
When orthotopically transplanted 3rdCSCcm tumours were examined in detail large 
regions composed of highly desmoplastic stroma could be seen surrounding clusters of cells that 
resembled the acini morphology. Moreover, multiple ducts were also found to co-localize with 
the acinar-like areas and few of them showed evidences of ADM transition (Figure 12A-B).  
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Figure 12. A) H&E staining of cluster cells areas with acinar morphology and ADM structures found in 3rd CSCcm 
primary tumours. B) Images showing evidences of ADM transition originated from acinar structures (arrowheads) 
indicated as 1, acino-ductal interphase as 2 and final ductal-like acquired phenotype 3. 
 
With the purpose to determine the acinar phenotype the presence of the protein Ptf1a was 
assessed. The resulting Ptf1a expression was specifically located in the cell clusters demonstrating 
a primary level of acinar differentiation. In addition, few PanIN lesions together with well-
differentiated ductal structures were found nearby the acinar-like cells and the intermediate stages 
of ADM. The expression of GFP was found to co-localized in the Ptf1a positive cell clusters 
validating the acinar cells as the lineage of CSCcm (Figure 13).  
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Figure 13. Cell clusters and few ductal cells were positive for the acinar marker Ptf1a. GFP was equally predominantly 
located in cell clusters and few cells from ductal epithelial cells. Micrographs original magnification 10x and 20x 
Supporting these evidences we detected the overexpression of Akt which through the 
PI3K/Akt pathway have been reported to be involved in the acinar dedifferentiation along with 
the accumulation of the β-catenin in the cytoplasm that has also been associated (Figure 14) (13-
16). Since it is important to elucidate whether the process of dedifferentiation plays an important 
role in the appearance of early events in pancreatic cancer our CSCcm model may be suitable for 
lineage tracing how acinar cells undergo into dedifferentiation losing its mature features and 
discern whether eventually develop a malignant transformation.  
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Figure 14. RT-qPCR of the relative transcript levels for PI3K, AKT and β-catenin in a panel of the samples obtained 
from serial transplantation. 
 
Molecular characterization confirms the acquisition of CSC features and a subsequent 
established PDAC pattern 
 To further validate the molecular nature of the CSCcm from PK8CM lines a transcriptome 
analysis by RNA-sequencing was performed. The expression quantification of 35,276 total 
described genes was estimated by Fragments Per Kilobase Million (FPKM) [log10(FPKM+1) 
value] and members from the transcriptional pancreatic progenitor network Pdx1, Hes1, Foxa2, 
Hnf1a, Hnf4a, Pax6, Nr5a2, Rbpj, Rbpgl, MafA and MafB were found to be expressed together 
with PDAC related hallmarks such as KRAS, Krt19, Col8a1, Col1a1, CXCR4, Muc1, Muc5aC, 
Mmp2 or MALAT1 as well as the most representative pancreatic CSC markers CD133, CD24a, 
EpCAM and CD44.nalysis for the differentially expressed genes (DEG) of single tumours were 
applied based on the following comparisons: i) 1st CSCcm (CSCcm8_1), 2nd CSCcm (CSCcm8_2) 
and 3rd CSCcm (CSCcm8_3) to CSCcm (CSCcm8), ii) 1st CSCcm to 2nd CSCcm and iii) 2nd 
CSCcm versus 3rd CSCcm. Venn diagrams indicated 1st CSCcm to bear a particular transcriptome 
programme among the 4 groups (Figure 15). 
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Figure 15. Molecular characterization. A) Venn diagram shows the differentially expressed genes (DEG) of the 5 
possible combinations among the CSCcm PK8 lines (left), and the combination of 1st CSCcm, 2nd CSCcm and 3rd 
CSCcm versus the CSCcm (right). 
 
 Thus, to gain insights of the similar expression patterns DEG data were arranged in a 
cluster analysis using the log10(FPKM+1) value which revealed CSCcm and 3rd CSCcm to be 
closer in expression whereas the 2nd CSCcm slightly differed and finally corroborated 1st CSCcm 
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as the most differentially expressed group (Figure 16). The gene identification and their 
corresponding localization within the heat map suggested possible new roles for already described 
genes in PDAC. PDGFRb and CDKN2a which are known to participate in the development and 
progression of PDAC (17, 18) co-localise with the CSC markers EpCAM and CD44 which leads 
to question their level of implication in the acquisition of the CSC-like genotype pattern (Figure 
16). 
 
Figure 16. Representative cluster analysis among the four CSCcm PK8 lines (right). The colour range represents the 
log10(FPKM+1) value from large (red) to small (blue). Main oncogenes and CSCs markers implicated in PDAC 
carcinogenesis were enlarged (left). 
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In order to elucidate potential candidates involved in the malignant transformation the 
distribution of differentially expressed genes (DESeq) was analysed for each of the 
aforementioned comparisons and represented in volcano plots |(log2 (FoldChange)|> 1&qvalue< 
0.005) (Figure 17). The transcript levels of pancreatic CSC markers CD24a, EpCAM and CD44 
were remarkably enhanced in 1st CSCcm whilst decreased in the subsequent generations. Instead, 
the popular hallmarks of PDAC KRAS, Krt19 and Myc were notably activated in 2nd CSCcm and 
persisted in 3rd CSCcm. Suggesting that the fate of the 1st CSCcm lineage may probably be 
established. The activation of Nr5a2 which its heterozygosity has been recently proposed to likely 
contribute to the occurrence of the PDAC (38), was sustained in 2nd CSCcm whereas in 1st CSCcm 
was dysregulated. Interestingly, the expression of GATA6 which have been found to be 
spontaneously lost in mouse model of Kras(G12V)-driven PDAC was not found in any of the 
groups (39). On the other hand, the original converted cell line CSCcm only differed from 2nd 
CSCcm in the increased expression of Krt19 and the activation of PI3K in 3rd CSCcm. Since 
tumours from all CSCcm lines were rich in desmoplastic stroma we sought for corresponding 
PSCs markers. Col8a1, Col1a1 and Col1a2 including TIMPs and Mmp2 which have been linked 
to tumour progression and invasion (19-21) were observed in 1st CSCcm. In addition, family 
members from CXC/CC chemokines Ccl2, Cxcl1 and Cxcl5 that are reported to favour the 
occurrence, maintenance and progression of the tumour (22) were also expressed in a correlated 
manner with PSCs markers. In overall, DESeq analysis consistently supported the gain of CSCs 
features and the established PDAC molecular pattern in the subsequent generations of CSCcm. 
Nonetheless a full transcriptome comparison between other RNA-seq datasets from other tumour 
types would be required.  
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Figure 17. Volcano plots for the differentially expressed genes screening (DESeq) distributed in significantly up-
regulated genes (red), donw-regulated (green) and not differentially expressed (blue). Threshold set as: 
|log2(FoldChange)|>1 and qvalue < 0.005. Representative scheme of the up- and down-regulated genes linked to PDAC 
occurrence and progression. 
 
“Mutation or not mutation-that is the question”  
 There is a wide range of genetic abnormalities in PDAC most of them derived from 
somatic single nucleotide variants (SNVs). In particular, the activation of the point mutation in 
Kras codon 12 has an 85-90% of prevalence in PDAC cases. Several mouse models have 
demonstrated that endogenous expression of oncogenic KrasG12D induces phenotypic changes 
at molecular and cellular levels that eventually recapitulate PDAC (7, 23-25). 
The variants obtained from the screening of repeated reads showed no evidences of single 
point mutation in Kras codon 12 nor 13 for any of the groups. In fact, the resulting variants were 
found to be located in the 3’-UTR region of the oncogene and were present in all CSCcm lines. 
To discern whether the Kras variants had any biological relevance in the malignant transformation 
of the CSCcm, and due to iPSCs have a high SNPs variability, we decided to screen the mouse 
strains sources from where the original fibroblast was obtained previously to the iPSCs 
reprogramming (26). Through the database platforms http://www.informatics.jax.org and 
http://www.sanger.ac.uk, DBA mouse strains which are supposed to compose the 50% of the 
fibroblast genome were found to harbour the exact Kras SNPs as CSCcm lines. Likewise, the 
presence of INDELs were not localised within the oncogene (Table 2). Thereby, there were no 
evidences of correlation between the SNPs found in Kras and the malignant transformation.    
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Table 2. Chromosomal SNPs coordinates within KRAS gene for CSCcm, 1st CSCcm, 2nd CSCcm and 3rd CSCcm 
PK8 lines. 
KRAS location: Chromosome 6: 145216699-145250239 
CRHOM POS ID REF ALT 
chr6 145216167 . T G 
chr6 145217363 . T C 
chr6 145218799 . C T 
chr6 145218800 . C T 
chr6 145219190 . C T 
chr6 145219338 . G A 
chr6 145220093 . C G 
chr6 145220160 . C T 
chr6 145220208 . G T 
CHROM: Chromosome ID of SNPs 
POS: Position of SNPs on corresponding chromosome 
ID: The ID of this variation in dbSNP 
REF: Reference genotype.  
ALT: SNP genotype 
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Discussion 
PDAC also known as pancreatic ductal adenocarcinoma is the most representative form 
of pancreatic cancer. PDAC is characterised by heterogeneous population of tumour cells 
structured in CSCs, differentiated cancer cells, tumour-associated PSCs and immune cells (1,4,6). 
Similarly to iPSCs, CSCs are considered as cells bearing stem cell properties that give rise to a 
diverse lineage of cancer cells. Driven by this convergence between CSCs and iPSCs, we opened 
a new avenue to generate new cell lines endowed of CSCs properties and enable to recapitulate 
the PDAC tumour phenotype. 
Based on the observations that the xenograft tumours generated from CSCcm lines 
recapitulate the ductal adenocarcinoma phenotype, and that puromycin-enriched primary cultures 
ensured to start over from the top of the hierarchy where CSCs are residing, we can postulate that 
CSCcm indeed give rise heterogeneous progenies composed by more differentiated cancer cells 
and PSCs in a hierarchical manner. Nevertheless, it is important to note that our results have 
pointed out 1st CSCcm lines as the potential candidates to represent the pancreatic CSCs. Thus, 
even though the conditioned medium from cancer cell lines provides an appropriate 
microenvironment able to initiate a malignant transformation, it is not until CSCcm get in touch 
with an in vivo system that the CSCs features become robust at the level of transcriptome. 
Supporting this, clear experimental evidences were seen when enriched primary cultures from 1st 
CSCcm generated a particular cell distribution wherein specific myofibroblast-like cells arose 
favouring the maintenance and stability of the CSCcm colonies. Therefore, the intervention of the 
organisms is still essential. Certainly, this reliance on in vivo systems is an unresolved matter that 
must eventually be overcome. Recent studies in the tumour microenvironment (TME) have 
provided new insights about how the cancerous niche plays a significant role in disease 
progression sustaining cell proliferation, activating invasion and metastasis (27). It has been 
appreciated for some time the influence of the TME, but the precise function of each constituent 
remains unknown. We expect that future analysis on the components of the conditioned medium 
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from cancer cell lines will help to elucidate new mechanisms to optimize the conversion of 
CSCcm and end up being independent of the murine organisms.  
Important early steps in pancreatic tumour initiation and progression are the genome 
reprogramming and dedifferentiation. Thus, the acino-ductal metaplasia has a relevant 
implication in the development of the pancreatic cancer. We observed that CSCcm tumours also 
generated ADM. In order to confirm the acinar phenotype the expression protein Ptf1a was sought 
in tumour samples and strong expression was found in the cell cluster structures. The expression 
of Hes1 together with Ptf1a are attributed to the characterization of centroacinar cells (CACs) 
which have been ascribed to bear stem-like features (7, 28). Since the RNA-seq expression 
quantification analysis indicate Hes1 as one of the most highly expressed genes, prompted us to 
question whether Ptf1a positive cells found in CSCcm tumours are either acinar or CACs. Further 
experiments will be required in order to clarify the real identity of the cells responsible for the 
ADM transition. 
PDGFRb and CDKN2a were found to be highly expressed in 1st CSCcm and strongly 
decreased in the rest of the groups. The overexpression of PDGFRb has been linked to a poor 
disease-free survival promoting metastasis in a cell-autonomous manner in mutant p53 mice and 
glioma stem cells have been reported to preferentially express PDGFRb which its activation 
promotes self-renewal and its depletion completely abrogated their tumorigenicity (17, 29). 
Intriguingly, CDKN2a acts as a tumour suppressor and is usually aberrant in 95% of pancreatic 
cancer. This alteration may be due to either an abnormal methylation or several reported germline 
mutations which leads to its inactivation (18, 35). When SNPs in CDKN2a were screened in 
CSCcm lines there were no evidences of single point mutations, but a single INDEL C<CAA 
located in the 3’-UTR region in CDKN2a was present only in 1st CSCcm group (Supplementary 
Table II). Nevertheless the same INDEL was found in the murine genome but neither relevant 
clinical nor functional information has been described so far. Thus, the sudden enhanced 
expression of PDGFRb may be related to the CSCs phenotype of 1st CSCcm. On the other hand, 
from the results obtained for CDKN2a we could not discern properly its implication, although its 
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sudden downregulation in 2nd CSCcm and maintained in 3rd CSCcm may be linked to the 
establishment of the PDAC phenotype. 
As it has been previously aforementioned, the frequency of single point mutations in Kras 
occur at 85-90% in pancreatic cancer (25, 30, 31). The activation of the oncogenic Kras together 
with its downstream effector Myc have been implicated in self-renewal and tumour plasticity 
events such as dedifferentiation (24). In our study we demonstrated that the tumorigenicity of 
CSCcm and consequent recapitulation of PDAC phenotype is not given by variants in the 
oncogene Kras since no formal evidences were found in SNPs analysis. However, this premature 
idea should be developed in extended eQTLs analysis which will provide information at the level 
of genotype-gene relation in addition to karyotype and genomic profiling analysis that would 
enable clear discrimination. MYC is generally overexpressed in PDAC. In accordance to this 
DESeq analysis showed increased expression of Myc in the 2nd CSCcm generation, however it is 
important to note that it was remarkably downregulated in 1st CSCcm. Recent findings on 
genome-wide DNA methylation profiling in pancreatic CSCs determine CpG sites annotated to 
Myc to be more methylated (5). This may be correlated with the overexpression of Dnmt3a and 
Dntm3b observed in 1st CSCcm and the subsequent downregulation in 2nd CSCcm. The 
predominant modification of DNMTs is the catalysis of the DNA methylation at 5-position 
cytosine. Dntm3a and Dnmt3b function as de novo methyltransferases and are highly expressed 
in embryonic cells and down-regulated in adult tissues. They have also been involved in self-
renewal and maintenance of colon cancer stem cells, and pancreatic cancer patients with higher 
levels have been significantly attributed to have an overall lower survival (41). Thereby, the 
activation of Kras and Myc are required but not sufficient to originate a PDAC tumour and their 
turnover between 1st CSCcm and more differentiated 2nd CSCcm may be tightly related to 
epigenetic alterations.   
In the context of inflammation, the combination of Kras and the activation of NFkB have 
been reported to induce the conversion of non-stem into stem cell properties of intestinal epithelial 
cells (IEC) through the stabilization of β-catenin (32). Despite there are not strong evidences in 
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pancreatic cancer models that implicate NFkB in PDAC progression (25), it was noteworthy that 
in 2nd CSCcm the levels of NFkB arose as Kras and Myc did. Experimental evidences are required 
to evaluate whether the acquisition of stem-like features may arise in a stochastic way since our 
model is based on iPSCs, however this fact may involve NFkB pathway in the prevalence of the 
CSCcm in pancreatic cancer cells progeny. On the other hand, inflammatory cells constitute an 
important part of the stromal tissue in pancreatic cancer and the existence of a consistent feedback 
between PSCs and CXC/CC chemokines family members makes to consider them as potential 
candidates to be effectors in the occurrence and progression of the tumour (19-22). Hence, these 
facts were corroborated with our DESeq data which indeed showed that the PSCs markers Col81a, 
Col1a1, Col1a2 were correlated with the expression of Ccl2, Cxcl1 and Cxcl5 chemokines 
interestingly with the stimulation of the CSCs markers overexpression. In addition, IL-33 is 
known to activate mast cells and stimulate pro-inflammatory cytokine production and has been 
found to be expressed in the nuclei of activated PSCs (36, 37). Intrapancreatic mast cells also 
express the cytokine stem cell factor (SCF) which plays a constitutively important role in 
proliferation and survival of pluripotent progenitor cells together with its receptor proto-oncogene 
tyrosine-kinase KIT (cKIT) (33, 34). Although pancreatic cancer cells express cKIT, its role in 
CSCs still needs to be elucidated. Interestingly, in the expression quantification analysis it appears 
to be overexpressed and DESeq results highlighted a differential expression of cKIT in 1st CSCcm 
indicating that it could be a potential target to abrogate the acquisition of CSCs properties. Thus, 
the aforementioned results notably remark the involvement of the inflammatory system as the 
main effector for the acquisition of the CSCs properties.  
Pancreatic CSCcm is a feasible model for pancreatic CSCs which recapitulates PDAC 
phenotype. It is important to note that the conversion process has not been achieved under any 
genetic manipulation and the present study has demonstrated a preliminary analysis where the 
expected single point mutations were not found. Therefore, our model may provide new insights 
about the actual occurrence of the pancreatic cancer leading to develop different approaches for 
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the early detection and find new effectors in order to target CSCs and abrogate the progression of 
this fatidic disease.  
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Material & Methods 
Cell culture 
Human pancreatic carcinoma cell lines PK-8 and KLM-1 (RIKEN cell Bank, Japan) were cultured 
in RPMI 1640 Sigma containing 10% FBS and 100 U/mL Penicillin. Undifferentiated mouse 
iPSC lines (RIKEN Cell Bank, Japan) were maintained on feeder layers of mouse embryonic 
fibroblasts (MEF) mitomycin C treated (ReproCell, Japan) in iPSCs medium (DMEM D5796 
Sigma, 15% FBS, 2mM L-Glutamine, 0,1mM NEAA, 50 U/mL Penicillin and 50 U/mL 
Streptomycin, 0,1mM 2-mercaptoethanol) supplemented with 1000 U/mL LIF, placed at 37ºC 
incubator, 5% CO2 and 100% humidity. The conditioned medium (CM) was prepared following 
the previously protocols published by our group, Chen et al. 2012 (9), the medium was collected 
from confluent dishes of PK-8 and KLM-1 cell lines populations centrifuged at 1000rpm for 5min 
and filtered using 0,22µm diameter pore filter (Millipore, Ireland).  
The conversion of the iPSCs into pancreatic cancer stem cells by CM (CSCcm) were generated 
as described below. For initiation of the PK-8 CSCcm and KLM-1 CSCcm lines established 
undifferentiated feeder-less iPSCs were seeded at 5x105 cells/mL and maintained with iPSCs 
medium, without LIF, combined with the CM obtained from PK-8 and KLM-1 cell lines.  The 
medium was changed every 24h and cells were sub-cultured every 3 days.  
For  1st CSCcm, 2nd CSCcm and 3rd CSCcm primary cultures of PK8CM and KLM-1CM mouse 
allografts were cut into small pieces in 2mL HBSS and transferred into a 15mL tube containing 
2mL of dissociation buffer (0,25% trypsin, collagenase IV, KSR, CaCl2) and were incubated at 
37ºC for 40min. The cellular suspension was transferred into a new 15mL tube and centrifuged 
at 1000rpm for 10min, iPSCs medium was added to terminate the digestion and again centrifuged 
at 1000rpm for 5min. The cell pellet was placed into appropriate volume of iPSCs medium 
without LIF and cells were seeded into a dish at a density of 5x105 cells/mL. After 24h cultures 
were enriched with 1 mg/mL puromycin and medium was replaced by the combination of CM 
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plus iPSCs medium. Medium was changed every 24h and cells were passaged every 3 days and 
cells were maintained no longer than the 5th passage.  
Sphere formation assay 
4×104 cells (1×104 cells/ml) were seeded on 6cm ultra-low attachment dishes (Corning 
incorporated, NY) with the iPSCs medium without FBS, supplied with Insulin-Transferrin-
Selenium-X (ITS-X, Life Technologies, CA). After 3 days primary spheres were dissociated at 
single cell with dissociation buffer (0,25% trypsin, collagenase IV, KSR, CaCl2) and 1x104 were 
transferred into a new ultra-low attachment 6cm dish for 3 days more. Spheroids with diameters 
above 100μm were judged as self-renewing spheroids. 
Animal experiments 
Nude mice (Balb/c -nu/nu, female, 4- to 6- week-old) were purchased from Charlesriver, Japan. 
For subcutaneous transplantation 104, 105 and 106 cells were suspended in 100µl of HBSS buffer. 
The tumour size and weight were recorded every 4 days. Pancreatic orthotopic transplantation 
was performed as previously described by Bruns et al. 1999 (40) with the only variation in the 
number of implanted cells (105/20µl and 106/20µl HBSS). The mice were housed under specific 
pathogen-free conditions in accordance with the plan of animal experiments reviewed and 
approved by the ethics committee for animal experiments of Okayama University under the IDs 
OKU-2008211, OKU-2009144, OKU-2010179 and OKU-2011-305. 
Histologic analysis 
Tumours were fixed in 4% PFA (WAKO, Japan) for 24h at 4ºC, washed in 20% sucrose solution, 
embedded in paraffin-wax and sectioned for histologic examination at 5µm. Sections were stained 
with hematoxylin and eosin (Hematoxylin solution, Sigma-Aldrich, MO; 0.5% Eosin Y, Sigma 
Aldrich, MO).  
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Immunohistochemistry (IHC) 
Before staining, paraffin was removed from sections using an oven at 60ºC for 30min, rehydrated 
and underwent antigen retrieval by treatment of 10mM citrate buffer (pH6.5) in a water bath at 
100ºC for 30min. After hydrogen peroxide blocking  (3% H2O2), slides were blocked with PBS + 
1.5% normal serum, incubated with primary antibodies overnight at 4ºC, rinsed with PBS, 
incubated with secondary antibody. Detection was accomplished using Ellite anti-rabbit and anti-
mouse ABC staining Vectastain kit (Vector, MI) and 3,30-diaminobenzidine tetrahydrochloride 
(DAB, Vector, MI). Counterstain was achieved with hematoxylin. Incubation of primary 
antibodies was carried out in 2.5% normal serum for rabbit polyclonal CD133 (1:100, #NB120-
16518, Novus Biologicals, USA), rabbit monoclonal GFP (1:200, #2956, Cell Signaling, MA), 
rabbit monoclonal MUC1 (1:100, #ab15481, Abcam, UK), mouse monoclonal MUC5aC (1:200, 
#NCL-MUC-5AC, Novocastra, Leica Biosystems Newcastle, UK), PTF1a mouse monoclonal 
(1:100 ,#sc-393011, Santa Cruz Biotechnology INC., Europe). Slides served as negative controls 
were incubated with PBS buffer.      
RNA preparation and RT-qPCR 
Total RNA was isolated by RNeasy Mini Kit (QIAGEN, Germany) and treated with DNase 
Amplification Grade (Invitrogen, CA). cDNA synthesis was performed using SuperScript III First 
strand kit (Invitrogen, CA). RT-qPCR was performed with Cycler 480 SYBR Green I Master mix 
(Roche, Switzerland). Primers used are listed below: 
Name  Primer sequence  (5‘ > 3‘) 
Fw CD24a TTCTGGCACTGCTCCTACC 
Rv CD24a GCGTTACTTGGATTTGGGGAA 
Fw CD133 CCTTGTGGTTCTTACGTTTGTTG 
Rv CD133 CGTTGACGACATTCTCAAGCTG 
Fw B-Catenin TCCCATCCACGCAGTTTGAC 
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Rv B-Catenin TCCTCATCGTTTAGCAGTTTTGT 
Fw PI3K TGGGACCTTTTTGGTACGAGA 
Rv PI3K AGCTAAAGACTCATTCCGGTAGT 
Fw Akt   GGCCCCTGACCAGACCTTA 
Rv Akt   GATAGCCCGCATCCACTCTTC 
Fw Pdx1 ATTCTTGAGGGCACGAGAGC 
Rv Pdx1 GGTCCGTATTGGAACGCTCA 
Fw Foxa2 TGGTCACTGGGGACAAGGGAA 
Rv Foxa2 GCAACAACAGCAATAGAGAAC 
Fw Hes1 CGGCATTCCAAGCTAGAGAAGG 
Rv Hes1 GGTAGGTCATGGCGTTGATCTG 
Fw Kras CAAGAGCGCCTTGACGATACA 
Rv Kras CCAAGAGACAGGTTTCTCCATC 
Fw EpCAM CTGGCGTCTAAATGCTTGGC 
Rv EpCAM CCTTGTCGGTTCTTCGGACTC 
Fw Tg Klf4 GCGAACTCACACAGGCGAGAAACC 
Rv Tg Klf4 TTATCGTCGACCACTGTGCTGCTG 
Fw Tg c-Myc CAGAGGAGGAACGAGCTGAAGCGC 
Rv Tg c-Myc TTATCGTCGACCACTGTGCTGCTG 
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RNA-seq library construction and sequencing 
Isolation of total RNA was performed using QIAGEN RNeasy kit. RNA samples were prepared 
for sequencing using Illumina TruSeq RNA Sample Preparation Kit and were sequenced in an 
Illumina HiSeq 2500. Sample preparation, RNA-sequencing and Bioinformatic analysis were 
carried out by Fligen, INC. (Novogene, Nagoya Japan). 
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